title: Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.
abstract: Antibody-drug conjugates (ADC) rely on the target-binding specificity of an antibody to selectively deliver potent drugs to cancer cells. IgG antibody half-life is regulated by neonatal Fc receptor (FcRn) binding. Histidine 435 of human IgG was mutated to alanine (H435A) to explore the effect of FcRn binding on the pharmacokinetics, efficacy, and tolerability of two separate maytansine-based ADC pairs with noncleavable linkers, (c-DM1 and c-H435A-DM1) and (7v-Cys-may and 7v-H435A-Cys-may). The in vitro cell-killing potency of each pair of ADCs was similar, demonstrating that H435A showed no measurable impact on ADC bioactivity. The H435A mutant antibodies showed no detectable binding to human or mouse FcRn in vitro, whereas their counterpart wild-type IgG ADCs were found to bind to FcRn at pH = 6.0. In xenograft bearing SCID mice expressing mouse FcRn, the AUC of 7v-Cys-may was 1.6-fold higher than that of 7v-H435A-may, yet the observed efficacy was similar. More severe thrombocytopenia was observed with 7v-H435A-Cys-may as compared to 7v-Cys-may at multiple dose levels. The AUC of c-DM1 was approximately 3-fold higher than that of c-H435A-DM1 in 786-0 xenograft bearing SCID mice, which led to a 3-fold difference in efficacy by dose. Murine FcRn knockout, human FcRn transgenic line 32 SCID animals bearing 786-0 xenografts showed an amplified exposure difference between c-DM1 and c-H435A-DM1 as compared to murine FcRn expressing SCID mice, leading to a 10-fold higher dose required for efficacy despite a 6-fold higher AUC of the c-H435A-DM1. The accelerated clearance observed for the noncleavable maytansine ADCs with the H435A FcRn mutation led to reduced efficacy at equivalent doses and exacerbation of clinical pathology parameters (decreased tolerability) at equivalent doses. The results show that reduced ADC clearance mediated by FcRn modulation can improve therapeutic index.
authors.affiliation: Amgen, Inc. , Seattle, Washington 98119, United States.
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Hamblett
authors.affiliation: Amgen, Inc. , Seattle, Washington 98119, United States.
authors.forename: Tiep
authors.initials: T
authors.lastname: Le
authors.affiliation: Amgen, Inc. , Seattle, Washington 98119, United States.
authors.forename: Brooke M
authors.initials: BM
authors.lastname: Rock
authors.affiliation: Amgen, Inc. , Seattle, Washington 98119, United States.
authors.forename: Dan A
authors.initials: DA
authors.lastname: Rock
authors.affiliation: Amgen, Inc. , Seattle, Washington 98119, United States.
authors.forename: Sophia
authors.initials: S
authors.lastname: Siu
authors.affiliation: Amgen, Inc. , Seattle, Washington 98119, United States.
authors.forename: Justin N
authors.initials: JN
authors.lastname: Huard
authors.affiliation: Amgen, Inc. , Seattle, Washington 98119, United States.
authors.forename: Kip P
authors.initials: KP
authors.lastname: Conner
authors.affiliation: Amgen, Inc. , Seattle, Washington 98119, United States.
authors.forename: Robert R
authors.initials: RR
authors.lastname: Milburn
authors.affiliation: Amgen, Inc. , Seattle, Washington 98119, United States.
authors.forename: Jason W
authors.initials: JW
authors.lastname: O'Neill
authors.affiliation: Amgen, Inc. , Seattle, Washington 98119, United States.
authors.forename: Mark E
authors.initials: ME
authors.lastname: Tometsko
authors.affiliation: Amgen, Inc. , Seattle, Washington 98119, United States.
authors.forename: William C
authors.initials: WC
authors.lastname: Fanslow
mesh_terms: D000818:Animals; D000906:Antibodies / Q000235:genetics / Q000378:metabolism*; D053282:CD27 Ligand / Q000378:metabolism; D002460:Cell Line; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D015395:Histocompatibility Antigens Class I / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D018796:Immunoconjugates / Q000737:chemistry / Q000494:pharmacology*; D007074:Immunoglobulin G / Q000378:metabolism*; D008453:Maytansine / Q000378:metabolism; D051379:Mice; D016513:Mice, SCID; D011961:Receptors, Fc / Q000235:genetics / Q000378:metabolism*
chemical_list: D000906:Antibodies; D053282:CD27 Ligand; D015395:Histocompatibility Antigens Class I; D018796:Immunoconjugates; D007074:Immunoglobulin G; D011961:Receptors, Fc; D008453:Maytansine; C100688:Fc receptor, neonatal
keywords: CD70; DM1; FcRn; H435A; antibody−drug conjugate; maytansine; noncleavable linker; therapeutic index